Stay updated with breaking news from Antoniod Assoro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The AURKA inhibitor alisertib has emerged as an agent of particular note, demonstrating early signals of efficacy with a manageable safety profile for the treatment of patients with locally advanced or metastatic breast cancer whose disease is resistant to endocrine therapies.
Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.
Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET...
Minnesota Partnership for Biotechnology and Medical Genomics announced today their 2021 research awardees. This marks the partnership's 17th year of...